www.biolinerx.com Open in urlscan Pro
89.200.137.201  Public Scan

Form analysis
0 forms found in the DOM

Text Content

BioLineRx
 * About
   * Our Team
   * Board of Directors
 * Pipeline
   * Motixafortide (BL-8040)
   * AGI-134
 * Clinical Development
   * Clinical Studies
   * Areas of Interest
 * Partnering
 * Investors
   * Share Performance
   * News & Events
   * Financials
   * Analyst Coverage
   * SEC Filings
   * Corporate Governance
   * Information Request
   * IR Contacts
 * Careers
 * Contact

 * About
   * Back
   * About
   * Our Team
   * Board of Directors
 * Pipeline
   * Back
   * Pipeline
   * Motixafortide (BL-8040)
   * AGI-134
 * Clinical Development
   * Back
   * Clinical Studies
   * Areas of Interest
 * Partnering
 * Investors
   * Back
   * Share Performance
   * News & Events
   * Financials
   * Analyst Coverage
   * SEC Filings
   * Corporate Governance
   * Information Request
   * IR Contacts
 * Careers
 * Contact


TRANSFORMING SCIENCE INTO MEDICINE

‘We are committed to developing novel compounds in oncology that will deliver
life-changing innovations for patients.’

Philip Serlin, CEO

PRESS RELEASE SEPTEMBER 27, 2022


BIOLINERX ANNOUNCES U.S. COMMERCIALIZATION PLAN FOR APHEXDA…



EVENTS




Corporate Presentation


PIPELINE

AGI-134

SOLID TUMORS

AGI-134 is a universal drug that evokes a vaccine effect via a unique,
hyper-acute, multi-arm mechanism that targets patient-specific neoantigens




PIPELINE

MOTIXAFORTIDE (BL-8040)

STEM CELL MOBILIZATION

Motixafortide (BL-8040) blocks the interaction between CXCL12 and CXCR4 leading
to robust mobilization of stem cells to the peripheral blood for collection and
transplant.




PIPELINE

MOTIXAFORTIDE (BL-8040)

SOLID TUMORS

Motixafortide (BL-8040) mobilizes immune cells to peripheral blood circulation,
leading to Increase in immune cell infiltration into tumors and reduction in
immunosuppression in tumor microenvironment.




PIPELINE

MOTIXAFORTIDE (BL-8040)

ACUTE MYELOID LEUKEMIA (AML)

Motixafortide (BL-8040) mobilizes leukemic cells from bone marrow’s protective
niche resulting in sensitization to anti-cancer treatment; induction of
apoptosis.




PIPELINE

AGI-134

SOLID TUMORS

AGI-134 is a universal drug that evokes a vaccine effect via a unique,
hyper-acute, multi-arm mechanism that targets patient-specific neoantigens




PIPELINE

MOTIXAFORTIDE (BL-8040)

STEM CELL MOBILIZATION

Motixafortide (BL-8040) blocks the interaction between CXCL12 and CXCR4 leading
to robust mobilization of stem cells to the peripheral blood for collection and
transplant.




PIPELINE

MOTIXAFORTIDE (BL-8040)

SOLID TUMORS

Motixafortide (BL-8040) mobilizes immune cells to peripheral blood circulation,
leading to Increase in immune cell infiltration into tumors and reduction in
immunosuppression in tumor microenvironment.




PIPELINE

MOTIXAFORTIDE (BL-8040)

ACUTE MYELOID LEUKEMIA (AML)

Motixafortide (BL-8040) mobilizes leukemic cells from bone marrow’s protective
niche resulting in sensitization to anti-cancer treatment; induction of
apoptosis.




PIPELINE

AGI-134

SOLID TUMORS

AGI-134 is a universal drug that evokes a vaccine effect via a unique,
hyper-acute, multi-arm mechanism that targets patient-specific neoantigens


View Pipeline Stem Cell MobilizationMotixafortide (BL-8040) Solid
TumorsMotixafortide (BL-8040) AMLMotixafortide (BL-8040) Solid TumorsAGI-134


PARTNERING

In-licensing
BioLineRx is committed to the identification, in-licensing and systematic
development of promising therapeutic candidates. Through this strategy,
BioLineRx is building a pipeline of powerful technologies in oncology.

Out-licensing
BioLineRx seeks to collaborate with leading global pharmaceutical companies with
a proven track record in clinical experience, for completion of the final phases
of the clinical trials, and commercial capabilities, to successfully bring our
innovative developments to market. We believe that this is the way to combine
our drug development expertise with your commercial development capabilities.





INVESTORS

CHANGE 0.01 (1.15 %)
VOLUME 130,323
EXCHANGE NASDAQ

0.85

20.50

CHANGE 0.00 (0.00 %)
VOLUME 0
EXCHANGE TEL-AVIV

Delayed up to 30 minutes - See terms
Delayed up to 30 minutes - See terms
InvestorsShare PerformanceAnalyst CoveragePress Releases
BioLineRx

©2022 BioLineRx Ltd. All rights reserved.

TermsPrivacy & Cookies

×